Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q16775
UPID:
GLO2_HUMAN
Alternative names:
Glyoxalase II
Alternative UPACC:
Q16775; A8K290; B4DP33; B4DRA7; E7EN93
Background:
Hydroxyacylglutathione hydrolase, mitochondrial, also known as Glyoxalase II, plays a crucial role in cellular detoxification. It catalyzes the hydrolysis of S-D-lactoyl-glutathione to glutathione and D-lactic acid, pivotal in maintaining cellular health.
Therapeutic significance:
Understanding the role of Hydroxyacylglutathione hydrolase could open doors to potential therapeutic strategies. Its involvement in detoxification processes positions it as a key target for enhancing cellular resilience against toxic metabolites.